SCHEMBL4099494

SCHEMBL4099494

Fc1ccccc1-c1nc(N2CCCC2)c2c(Cl)cccc2n1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HIF1A Q16665 2/20 0.65
ABCB1 P08183 1/20 0.60
MAPT P10636 6/20 0.55
KMT2A Q03164 4/20 0.47
TDP1 Q9NUW8 4/20 0.47
MEN1 O00255 3/20 0.47
HSD17B10 Q99714 2/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
SMAD3 P84022 1/20 0.47
LMNA P02545 3/20 0.47
ELANE P08246 1/20 0.46
ACP1 P24666 2/20 0.43
TSHR P16473 3/20 0.42
MAPK1 P28482 2/20 0.42
KDM4E B2RXH2 2/20 0.42
ALDH1A1 P00352 2/20 0.42
CASP1 P29466 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4084544 0.90 ABCB1 (0.67) HIF1AABCB1MAPTKMT2ATDP1
SCHEMBL4090727 0.90 ABCB1 (0.73) HIF1AABCB1MAPTKMT2ATDP1
SCHEMBL4091224 0.90 HIF1A (0.71) HIF1AABCB1MAPTKMT2ATDP1
SCHEMBL1084330 0.85 SMAD3 (0.67) HIF1AABCB1MAPTKMT2ATDP1
SCHEMBL4095765 0.84 MAPT (0.53) HIF1AABCB1MAPTKMT2ATDP1
SCHEMBL4755285 0.84 MAPT (0.52) HIF1AABCB1MAPTKMT2ATDP1
SCHEMBL12946027 0.82 ABCB1 (0.56) HIF1AABCB1MAPTKMT2ATDP1
SCHEMBL4099740 0.80 KMT2A (0.50) HIF1AMAPTKMT2ATDP1MEN1
SCHEMBL1083814 0.80 HIF1A (0.97) HIF1AABCB1MAPTKMT2ATDP1
SCHEMBL4092379 0.80 ABCB1 (0.67) HIF1AABCB1MAPTKMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2009-08-20 US disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed
WO-2008157500-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE KALYPSYS, INC. (US) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209536-A1 AMINOQUINAZOLINE CANNABINOID RECEPTOR MODULATORS FOR TREATMENT OF DISEASE CNR2, CNR1, GPR18 HIF1A 1496/4885ABCB1 2120/4885MAPT 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.